OptimizeRx Q2 revenue falls 30% to $20.5M, swings to GAAP net loss; reaffirms FY guidance

OptimizeRx Corp

Q2 revenue $20.5M, down 30% YoY from $29.2M; GAAP net loss $(0.7)M or $(0.04)/share vs $1.5M net income ($0.08) in Q2 2025.
Non-GAAP net income $3.1M ($0.16 diluted) vs $3.7M ($0.19) prior year; adjusted EBITDA $4.9M vs $5.8M.
FY2026 guidance reaffirmed: revenue $95-100M and adjusted EBITDA $21-25M.
CFO Ed Stelmakh steps down Dec 31, 2026; Andy D'Silva becomes CFO and Heather Favazza CAO effective Jan 1, 2027.
Stelmakh gets 12 months base salary ($450K/yr), $247.5K bonus lump sum, COBRA; advisory role through Dec 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.